



**Top 10 Cancer Morbidity among Children**  
**CaLaBaRZon, Year 2014-2022**

2014					
Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C39.0; Upper respiratory tract infection part unspecified	6,058	3,908	1,198	579	11,743
C44.8; Overlapping lesion of skin	36	19	3	3	61
C77.0; Lymph nodes of head, face and neck	10	10	5	1	26
C03.9; Gum, unspecified	7	8	8	1	24
C43.2; Malignant melanoma of ear and external auricular canal	8	11	0	5	24
C41.9; Bone and articular cartilage, unspecified	3	3	1	1	8
C30.1; Middle ear	4	1	0	1	6
C43.9; Malignant melanoma of skin, unspecified	4	0	2	0	6
C16.9; Stomach, unspecified (CANCER/CARCINOMA, GASTRIC, PRIMARY SITE, MALIGNANT)	1	0	1	1	3
C04.8; Overlapping lesion of floor of mouth	2	0	0	0	2
2015					
Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C39.0; Upper respiratory tract, part unspecified	1,121	635	220	99	2,075
C44.8; Overlapping lesion of skin	7	8	6	0	21
C03.9; Gum, unspecified	5	5	1	1	12
C77.9; Lymph node, unspecified	8	8	4	0	20
C16.9; Stomach, unspecified (CANCER/CARCINOMA, GASTRIC, PRIMARY SITE, MALIGNANT)	5	3	4	1	13
C44.1; Skin of eyelid, including canthus	0	6	0	0	6
C18.9; Colon, unspecified (CANCER, COLON, PRIMARY, MALIGNANT) (COLONIC MALIGNANCY)	3	0	0	0	3
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	3	1	0	0	4
C49.9; Connective and soft tissue, unspecified (SARCOMA, PRIMARY, MALIGNANT, SITE UNSPECIFIED)	0	0	1	1	2
C82.9; Follicular non-Hodgkin's lymphoma, unspecified (NODULAR LYMPHOMA/LYMPHOSARCOMA) (FOLLICULAR LYMPHOSARCOMA)	1	1	0	0	2
2016					
Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C39.0; Upper respiratory tract, part unspecified	1,397	693	305	114	2,509
C03.9; Gum, unspecified	12	9	5	1	27
C44.8; Overlapping lesion of skin	7	4	0	0	11
C77.9; Lymph node, unspecified	3	2	5	0	10
C68.9; Urinary organ, unspecified	2	6	0	0	8
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	4	2	0	1	7
C49.9; Connective and soft tissue, unspecified (SARCOMA, PRIMARY, MALIGNANT, SITE UNSPECIFIED)	3	2	1	1	7
C77.0; Lymph nodes of head, face and neck	5	1	1	0	7

C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	5	0	0	0	5
C30.1; Middle ear	2	1	1	0	4
<b>2017</b>					
Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C39.0; Upper respiratory tract, part unspecified	1,862	1,253	494	294	3,903
C03.9; Gum, unspecified	33	20	12	5	70
C09.9; Tonsil, unspecified	11	12	6	2	31
C77.9; Lymph node, unspecified	7	9	2	1	19
C11.9; Nasopharynx, unspecified (CANCER/CARCINOMA, NASOPHARYNGEAL, PRIMARY SITE, MALIGNANT)	6	4	2	1	13
C44.8; Overlapping lesion of skin	5	6	1	0	12
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	12	3	1	0	16
C16.9; Stomach, unspecified (CANCER/CARCINOMA, GASTRIC, PRIMARY SITE, MALIGNANT)	3	2	2	0	7
C49.9; Connective and soft tissue, unspecified (SARCOMA, PRIMARY, MALIGNANT, SITE UNSPECIFIED)	2	2	2	1	7
C77.0; Lymph nodes of head, face and neck	1	2	1	2	6
<b>2018</b>					
Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C39.0; Upper respiratory tract, part unspecified	1,350	837	455	231	2,873
C03.9; Gum, unspecified	22	20	17	7	66
C09.9; Tonsil, unspecified	9	16	9	3	37
C44.8; Overlapping lesion of skin	15	5	3	2	25
C77.9; Lymph node, unspecified	7	13	6	3	29
C43.2; Malignant melanoma of ear and external auricular canal	6	7	2	1	16
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	7	3	0	1	11
C49.9; Connective and soft tissue, unspecified (SARCOMA, PRIMARY, MALIGNANT, SITE UNSPECIFIED)	2	1	3	2	8
C16.9; Stomach, unspecified (CANCER/CARCINOMA, GASTRIC, PRIMARY SITE, MALIGNANT)	4	2	0	1	7
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	5	0	0	0	5
<b>2019</b>					
Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C39.0; Upper respiratory tract, part unspecified	647	499	274	150	1,570
C03.9; Gum, unspecified	26	30	21	11	88
C77.0; Lymph nodes of head, face and neck	11	8	6	4	29
C44.8; Overlapping lesion of skin	16	6	3	0	25
C09.9; Tonsil, unspecified	8	7	5	2	22
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	2	2	1	0	5
C00.9; Lip, unspecified	2	1	1	0	4
C14.0; Pharynx, unspecified	2	1	0	0	3
C41.1; Mandible	2	1	0	0	3
C18.1; Appendix	0	1	1	0	2
<b>2020</b>					
Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C39.0; Upper respiratory tract, part unspecified	271	184	81	64	600

C03.9; Gum, unspecified	8	7	7	5	27
C44.8; Overlapping lesion of skin	5	8	5	1	19
C77.9; Lymph node, unspecified	4	10	3	1	18
C09.9; Tonsil, unspecified	0	4	3	3	10
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	9	2	1	1	13
C81; Hodgkin's disease (LYMPHOMA)	2	0	2	1	5
C38.0; Heart	2	1	0	1	4
C41.1 Mandible	0	3	1	0	4
C16.9; Stomach, unspecified (CANCER/CARCINOMA, GASTRIC, PRIMARY SITE, MALIGNANT)	0	2	1	0	3

**2021**

Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C39.0; Upper respiratory tract, part unspecified	372	178	87	94	731
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	9	3	0	0	12
C44.8; Overlapping lesion of skin	7	2	1	0	10
C03.9; Gum, unspecified	2	4	1	1	8
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	5	0	0	0	5
C77.9; Lymph node, unspecified	1	2	2	0	5
C50; Malignant neoplasm of breast	0	0	1	1	2
C77.0; Lymph nodes of head, face and neck	0	1	0	1	2
C81; Hodgkin's disease (LYMPHOMA)	0	0	2	0	2
C06.8; Overlapping lesion of other and unspecified parts of mouth	1	0	0	0	1

**2022**

Disease	Age group				Total
	1-4	5-9	10-14	15-19	
C16.9; Stomach, unspecified (CANCER/CARCINOMA, GASTRIC, PRIMARY SITE, MALIGNANT)	38	14	4	7	63
C44; Other malignant neoplasms of skin	9	2	0	1	12
C30.0; Nasal cavity	8	3	0	1	12
C39.0; Upper respiratory tract, part unspecified	5	1	0	2	8
C43; Malignant melanoma of skin	4	1	1	1	7
C44.3; Skin of other and unspecified parts of face	3	1	2	1	7
C06.9; Mouth, unspecified (CARCINOMA, ORAL, MALIGNANT, PRIMARY SITE)	3	2	1	1	7
C44.6; Skin of upper limb, including shoulder	2	2	0	0	4
C77.9; Lymph node, unspecified	3	0	0	0	3
C43.9; Malignant melanoma of skin, unspecified	1	1	0	0	2

Source: FHSIS Database as of May 12, 2022. Note: No FHSIS Data from Year 2010-2013

FOI#DOH-752200060347 | #DOH-462797751232

Prepared by:

  
Cristine D. Alcaraz  
Data Controller III

Noted by:

  
Cyrus Miguella Hilomen  
Statistician II / OIC - FHSIS Coordinator

Approved by:

  
John Bobbie M. Roca, RN, MAN, PHSAE  
Nurse V / RESU Head

Date Prepared: 06/3/2022